Last reviewed · How we verify
Requip (ropinirole)
At a glance
| Generic name | ropinirole |
|---|---|
| Sponsor | GSK |
| Target | D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Parkinson's disease
- Restless legs
Common side effects
- Nausea
- Dizziness
- Asthenic condition
- Dyspepsia
- Vomiting
- Leg edema
- Pain
- Increased sweating
- Dry mouth
- Dependent edema
- Chest pain
- Anorexia
Serious adverse events
- Syncope
- Hallucinations/psychotic-like behavior
- Withdrawal-emergent hyperpyrexia and confusion
- Fibrotic complications
- Retinal pathology
- Orthostatic hypotension
- Dyskinesia
- Impulse control/compulsive behaviors
- Augmentation and early-morning rebound in RLS
- Falling asleep during activities of daily living
Key clinical trials
- Transdermal Lisuride: a Double-blind, Randomized, Active- and Placebo-controlled Multi-centre Phase III Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) (Phase 3)
- Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD) (Phase 4)
- An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets (Phase 2)
- A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate R (Phase 3)
- Gait Pattern Analysis in Neurological Disease (N/A)
- A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects (Phase 1)
- A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optima (Phase 3)
- Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Requip CI brief — competitive landscape report
- Requip updates RSS · CI watch RSS
- GSK portfolio CI